JD

JD is a study in contrasts this year. Revenue grew +17.9% to $187B — the fastest pace in the five-year history shown (FY2022-24 grew only ~2-4% annually) — yet operating income collapsed 92.5% to just $397M, net income fell 45.9% to $3.31B, and diluted EPS halved to $0.92. That divergence (accelerating top line, evaporating operating profit, with R&D up 36.3% and capex up 52.5%) is the signature of a large, deliberate investment push rather than demand weakness. Operating margin is now a razor-thin 0.2% and net margin 1.8%. The whole call hinges on whether that spend earns a return.

The balance sheet gives JD the room to make this bet. Cash rose 32.4% to $19.7B, equity is $32.2B against $57.4B of liabilities (1.78x — moderate, not stressed), the current ratio is a comfortable 1.22x ($53.5B/$43.8B), and debt is small. Management is leaning in on capital return, paying $3.06B of buybacks plus $1.48B of dividends — $4.54B, more than the full $3.31B of net income. But note operating cash flow fell 65.9% to $2.72B, so this year they returned more cash than the business generated, drawing on the cash pile. That is fine once, a problem if it persists alongside compressed margins.